Jamaica Parliament Decriminalizes Small Amounts of Marijuana

http://jurist.org/paperchase/2015/02/jamaica-parliament-decriminalizes-small-amounts-of-marijuana.php

The Jurist

[JURIST] The Jamaican House of Parliament [official website] passed an act Tuesday decriminalizing small amounts of marijuana. Under the new law, possession of less than two ounces of marijuana is considered a petty offense [AP report] punishable by a ticket.

Beyond consumption, the legislation allows individuals to cultivate up to five plants on any premises. Minister of National Security Peter Bunting [official website] issued a statement following the act’s passage, reinforcing the governments intent to continue combating transnational drug trafficking and illegal cultivation of marijuana.

The new law also lays the ground work for the establishment of a licensing agency to regulate a lawful medical marijuana industry in the country. Additional regulations regarding the licensing agencies and the establishment of the medical marijuana sector are expected in the coming months.

Jamaica is the most recent country to join a growing global trend of loosening anti-marijuana laws [JURIST backgrounder]. Earlier this week Alaska’s voter initiative legalizing marijuana [JURIST report] use took effect, making it the third state, along with Colorado and Washington, to legalize recreational marijuana. In November voters in Alaska, Oregon and Washington, DC, voted [JURIST report] to legalize recreational marijuana. Also in November the head of the UN Office on Drugs and Crime (UNODC) [official website] expressed concern that the legalization of marijuana by some US states is not compatible with existing international drug conventions.

About Paper Chase

Paper Chase is JURIST’s real-time legal news service, powered by a team of 30 law student reporters and editors led by law professor Bernard Hibbitts at the University of Pittsburgh School of Law. As an educational service, Paper Chase is dedicated to presenting important legal news and materials rapidly, objectively and intelligibly in an accessible format.

 

Senate Organization Chart for the 114th Congress

http://www.senate.gov/pagelayout/reference/e_one_section_no_teasers/org_chart.htm

The Virtual Reference Desk provides resources about Senate Leadership, committees, and officers.

 

Alex Garland’s Black Lives Matter 2015: Activists March Through Seattle’s Central District in Protest for Police Accountability

http://thedignityvirus.com/2015/01/10/black-lives-matter-activsts-march-through-seattles-central-district-in-protest-for-police-accountability/

More than 150 activists marched from Martin Luther King Jr. Memorial Park to the King County Juvenile Detention Center on 12th Ave. in Seattle during a demonstration for police accountability.

Activists took to the streets, stopping at several intersections along the way for moments of silence and speak-outs. Support was shown as the protest marched down Rainier Ave. as people put their fists up or raised hands in a sign of solidarity.

From the Facebook event page…

“We, as young people, have chosen to come forth and call out the many inequalities within the current Criminal Justice System. This system has blatantly devalued, dehumanized, and dismissed people of color. The Black and African-American Communities in the United States have especially been targeted. We are outraged with this systemic failure.

To not act is an injustice within itself. As citizens we need to step up and no longer allow law enforcement to abuse our powers. The current state of the Criminal Justice System has increased persecution of Black and African-American people.

We will no longer tolerate the mistreatment, lack of support, and denied opportunities for this community. We are addressing these issues through peaceful protests, unifying actions, and productive dialogues.

We invite law enforcement, elected officials, and community members to join the movement towards police accountability.

In order to ensure the mission of this protest is accurately portrayed we have come up with some guidelines. They are as follows:

***NO VIOLENCE***
• Do NOT touch the police officers
• Do NOT deface/destroy city or private property
• Do NOT move city or private property

If you do not follow these guidelines you will be asked to stop. If your actions continue you will be asked to leave.”

Peace & Love,
Women of Color for Systemic Change

“Black Lives Matter.” – Protest for Police Accountability

420 Leaks: Washington State I-502 MMJ Law Scandal

From Washington State activist John Novak January 9, 2015:

This article includes a large number of links to public records, news articles and other information. If this email does not contain all the hyperlinks, please go to the following links..Please be patient as the site is experiencing heavy volume of visitors and is being adjusted accordingly.

Online at: http://420leaks.com/?p=689
On Facebook at:
https://www.facebook.com/notes/420leaks/i-502-opma-mmj-public-records-and-the-partnership/761929917211137

(We will follow up this email soon with our proposed solutions.)

Subject: I-502: OPMA, MMJ, Public Records and the “Partnership”

By John Worthington (background research also by Arthur West, John Novak)
(All exhibit links to box.com are from public record files in PDF format)
One of the main goals of Initiative I-502, as originally written and passed, was allegedly to create a policy change from enforcing marijuana crimes, to properly enforcing property crimes by ‘legalizing” marijuana for persons over 21.
Once the “legalization” initiative passed, the marijuana prohibition stakeholders, AKA the “partnership” went to work to reverse the policy goals outlined in I-502. (Exhibit 1 https://app.box.com/s/rmgcsqu9eknlx5zbp7o9 )
The “partnership” immediately orchestrated numerous secret meetings for I-502 implementation, to further remarket the marijuana prohibition bureaucracy and directed the Washington State Liquor Control Board (WSLCB) take steps to get rid of medical marijuana.
 
Despite the best efforts to hide these meetings, enough information began to leak out to the marijuana activists, that they were able piece together how the “partnership,” influenced the WSLCB. The documents they obtained show how the “partnership” set out to increase local law enforcement funding and de-incentivize medical marijuana.
These public records obtained by various individuals and advocacy groups also show the subversion began with the secret Association of Washington Cities (AWC – a non-profit made up of corporations and government agencies) and law enforcement meetings with the Washington State Liquor Control Board.
The messages and goals for this new Meta organization was clear, get rid of medical marijuana, and divert I-502 revenue to the cities and counties.
According to the notes from these secret Liquor Control Board meetings with local, state and federal agencies set up by the AWC, medical marijuana was no longer needed because the State now had a “legal” marijuana system.
The notes also described in detail how the “partnership” wanted medical marijuana to be repealed and also wanted local law enforcement budget increases. The LCB then took this agenda to the editorial boards of newspapers around the state. (Exhibit 2 https://app.box.com/s/o4cips7jho2mejgho5cs See also https://app.box.com/s/asxmcnzjp2zxj4fbksxe)
The WSLCB arranged to have the legislature “give them cover”, by creating legislation that would allow them a “place at the table,” for medical marijuana discussions. This strategy is outlined in an email from WSLCB board member Chris Marr to the agency director, Rick Garza. (Exhibit 3 https://app.box.com/s/di9dkswq8v250c5ihs8u )
The email from Marr also introduced the other players in the Meta leadership. These players, knowing or unknowing, were Senator Ann Rivers and I-502 entrepreneur Ezra Eickmeyer. (Exhibit 4 https://app.box.com/s/y90s7ff4z4sho6s8wxb0 )
 
Eickmeyer, through Senator Rivers, proceeded to draft SB 5887, which proposed to create a medical marijuana work group, however, the bill did not pass.
Senator Rivers and Eickmeyer then acted to get a medical marijuana work group passed “Amendment #224” in the state’s budget bill, SB 5034, to which Senator Jeanne Kohl-Welles objected to because “too many conclusions would be drawn behind closed doors. Senator Kohl-Welles put out an email on June 2, 2014 addressing concerns about the process.

“It has also has resulted in a high level of concern on the part of many patient and other advocacy groups — including even outright opposition being expressed in rallies and demonstrations. I am concerned that we would be handing over too much of our responsibility to a regulatory agency. I also worry that too many conclusions would be drawn behind closed doors, and that the process for creating these rules would circumvent public input.

In many ways, the LCB has a vested interest in diverting business from the medical collectives now operating and into the retail stores when they open early next year. It is easy to argue the LCB also has a vested interest in wanting to add to its regulatory scope, and bring the medical cannabis industry into its system. This may turn out to be the end result down the road, or it may be determined that another state agency should have that responsibility.

For these and other reasons, I think it best to have the LCB focus on its task at hand, that given to them by the voters in approving I-502 — an initiative that specifically mentions it will have no effect on medical cannabis laws.”

Meanwhile, the rest of the “partnership” worked behind the scenes to create law enforcement funding legislation for the “partnership.” The Washington State Patrol’s Investigative Assistance Division (IAD), was tasked to help “shape” I-502 policy. (Exhibit 6 https://app.box.com/s/eepfhipts7ty6svlvxzp )
The IAD is staffed by officers considered to be loaned state employees to the federal government subject to the Westfall and Federal Tort Claims Act.
Essentially, the federal government also had a hand in I-502 secret rulemaking process through the cross designated members of the WSP and in direct meetings with the DEA and U.S. Attorney’s office.
Soon after the passage of initiative I-502, the broad and powerful “partnership” had managed to convert the policy goals of redirecting law enforcement funding to property crimes to adding local law enforcement funding and getting rid of medical marijuana.
The Washington State Liquor Control Board had arranged its “place at the table”, and the “partnership”, managed to set forth a mechanism to glean law enforcement funding increases and interfere with medical marijuana laws when I-502 appeared to advertise just the opposite. (Exhibit 7 https://app.box.com/s/uhke9k9wda5tdjsx93cs )
For its part the work group, began its job of eliminating or de-incentivizing medical marijuana under the guise of merging it with recreational marijuana. (Exhibit 8 https://app.box.com/s/rdkfowosyuwyzodgyzs4 )
The medical marijuana work group had the same open public meetings problem as the I-502 implementation process. They also did not want the public to hear who it was they were working with in private and publically show how they arrived at its decisions.
The Governor’s office, with help from the local U.S. Attorney Jenny Durkan did their part by making sure the public knew that the medical marijuana situation was “untenable”. (Exhibit 9 https://app.box.com/s/c5m8ogtl8hod59lmewbr )
The urgency for a “robust” regulatory system for marijuana was further ratcheted up with the use of a document referred to as the “Cole Memorandum”, which was actually requested by the LCB, and not a mandate generated by the U.S. Attorney’s office at the request of the Governor’s office. (Exhibit 10 https://app.box.com/s/o4cips7jho2mejgho5cs )
The following legislative session in 2014, SB 5887 and a new bill from Senator Jeanne Kohl Welles SB 6178, offered two approaches on how to integrate and de-incentivize medical marijuana. Representative Eileen Cody also proposed HB 2149 that same legislative session.
 
All of the bills contained language which highlighted the recommendations of the medical marijuana working group. The battle of killing medical marijuana in the 2014 legislative session began in earnest.
The legislators had several major hurdles to clear in order to kill medical marijuana. The most formidable of which was the fiscal impacts of the “robust” regulatory system which now included more law enforcement funding not included in the I-502 earmarks.
The fiscal notes to the Ways and Means and House Finance committees, which were put forth at the last second, did not include the actual cost of implementing the ratcheted up “robust” marijuana regulatory scheme.
Furthermore, the small business impact studies were incomplete further misleading the actual financial impact of the medical marijuana killing legislation.
Some legislators refused to consider more law enforcement funding because the initiative claimed to be saving money on law enforcement funding. (Exhibit 11 https://app.box.com/s/j9aq6xp77d3ut7fdlg1v )
 
“The argument for the initiative was that it’s going to lower public safety costs, and now they’re saying it’s going to increase public safety costs with absolutely no data. (It’s) troubling,” said House Finance Committee Chairman Reuven Carlyle (D-Seattle) in an interview.
Many marijuana activists claimed victory when all the medical marijuana bills failed to pass out of the 2014 legislative session.
The 2015 legislative session is underway and the legislature should be informed of what the I-502 rule making process has become so they can properly achieve policy goals set forth by the public.

Cannabinoids Create Log Jam at U.S. Patent Office

http://globenewswire.com/news-release/2014/09/18/666960/10099121/en/Cannabinoids-Create-Log-Jam-at-U-S-Patent-Office.html

GeoNovus Minerals Corp.

VANCOUVER, British Columbia, Sept. 18, 2014 (GLOBE NEWSWIRE) — There are 5,000 pending patents on different cannabinoid compounds at the U.S. Patent Office – most of them registered by Pharmaceutical companies who are intending to commercialise the naturally occurring compound found in the Cannabis Sativa.

GeoNovus (CSE:GNM) (GMINF-USA) is a Canadian company positioning itself to benefit from a research explosion that is expected to drive the legal marijuana market from $1.53-billion in 2013 to $2.57-billion by the end of 2014.

On June 26, 2014 GeoNovus announced that it has signed a letter of agreement with a Uruguay company actively working in multiple areas of the medical marijuana, industrial hemp and cannabinoid science industries to develop products for consumer use.

The initiation of the agreement within Uruguay gives GeoNovus pioneering and exclusive rights to acquire and participate in multiple business ventures in Uruguay including: growing facilities, cannabinoid product development, medicinal trials and industrial hemp product development.

Uruguay recently became the first country in the world to legalize the sale cultivation and distribution and consumption of cannabinoids in December of 2013.

“I got involved with medical marijuana in 2001, when my mother was diagnosed with ovarian cancer,” stated Julian Strauss, GeoNovus Uruguayan Operations Manager in an exclusive interview with Financial Press, “we discovered it had medicinal properties not available from conventional drugs.”

In Vancouver, BC Strauss collaborated with researchers from the University of British Columbia and formed a compassion club, developed “partial decarboxylation delivery systems” for patients dealing with painful side-effects of therapeutic treatments for multiple sclerosis and cancer. The club organised informal trials, and the results went off the charts.

“At that point I started reaching out to doctors,” stated Strauss, “We collected patients, grew medical marijuana, created oil extracts and collaborated with health authorities and doctors. It was impossible grow enough marijuana to satiate the demand for medicinal oils.”

The team created proprietary collection systems to produce oils on an industrial level, anticipating that Canada would deregulate, and they could begin human trials with the developed intellectual property or “IP”.

“The de-regulation did not come in a way that was helpful to us,” stated Strauss, “The narrative in Canada changed to guys in dread-locks promising to save the world. So I got on a plane to Uruguay and began discussions with the Latin American scientific community, and also with regulators and legislators. We are now building a legal and logistical framework for the development and commercialisation of cannabinoids in partnership with Uruguayan government bodies, universities, and growers clubs.”

Strauss believes the quickest route to cash flow in the marijuana industry is by creating infrastructure for clinical hemp and marijuana trials, and then creating protocols for lab studies, full-spectrum therapies, chemical and mechanical fiber analysis.

“The 5,000 pending patents tell the story,” stated Strauss, “Research into the uses of cannabinoids is about to explode. We can offer entrepreneurial companies an environment to collect data, run trials and ultimately register intellectual property. For providing this service in Uruguay, our company will maintain a royalty percentage. We believe there is a great financial opportunity in helping to legitimize cannabis technology companies.”

“Dry cannabis is a smokescreen thrown up to regulate the medicinal value of cannabis,” explains GeoNovus President Michael England, “This is not where we see the big business opportunity. There is a $200 billion dollar industry waiting in the wings for deregulation. We intend to create manufacturing protocols for specific pathologies. By establishing operations in Uruguay, we can get in on the ground floor.”

Cannabinoids are one of the only compounds in nature that naturally break down the blood barrier in the spine and brain. MRIs and CAT scans of the body’s reaction to therapeutic treatment confirm the endless potential for hemp-based homeopathic remedies.

“Every pharmaceutical company in the world is creating allopathic carbon-based lab derivatives of cannabinoids to try and mimic the natural function found within the plant’s genome,” stated England, “But natural cannabinoids are the answer, and for that they will need a scientific and regulatory environment that promotes experimentation and clinical trial. Uruguay provides us with all of these factors as well as access to a significant pool of professional expertise – Big Pharma will be taking notice.”

Therapeutic cannabinoid treatments for all types of ailments from multiple sclerosis and cancer to headaches and seizures are quickly becoming a popular alternative to traditional chemo and medicines. Ground-breaking cannabinoid research being conducted by companies like GeoNovus in “Cannabis friendly” countries like Uruguay will pave the way for the future of these emerging alternative therapies.

GeoNovus is currently trading at $0.04 with a market cap of only $2 million under the symbol GNM on the Canadian Securities Exchange (CSE) and GMINF in the USA.

Legal Disclaimer/Disclosure: A fee has been paid for the production and distribution of this Report. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this article should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. Financial Press makes no guarantee, representation or warranty and accepts no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of the authors only and are subject to change without notice. Financial Press assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this article and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this article.

Also, please note that republishing of this article in its entirety is permitted as long as attribution and a back link to FinancialPress.com are provided. Thank you.

GeoNovus Minerals Corp
1220 789 West Pender Street
Vancouver, BC, Canada
V6C, 1H2
Toll Free: 1-888-945-4770
Phone: 604-683-3995
Fax: 604-683-3988
Email:

– See more at: http://globenewswire.com/news-release/2014/09/18/666960/10099121/en/Cannabinoids-Create-Log-Jam-at-U-S-Patent-Office.html#sthash.v2NSqKOD.dpuf

U.S. Sailors Won Key Court Decision to go Forward with Class Action Lawsuit Against Tepco

http://fukushima-diary.com/2014/11/u-s-sailors-won-key-court-decision-go-forward-class-action-tepco-ge-toshiba-hitachi-etc/

U.S. Sailors won key court decision to go forward with class action against Tepco, GE, Toshiba and Hitachi etc.

 Following up this article.. The US Navy sailors’ complaint refers to Fukushima Diary [URL]

The federal judge, Janis L. Sammartino published the decision to let U.S Navy Sailors go forward with the United States District Court in San Diego against Tepco. Tepco was insisting the court should be in Japan because most of the “witnesses are in Japan”, and “the Japanese government may refuse to disclose crucial information or make witnesses available in a U.S. court”.

However the Federal judge concluded it should be in U.S court for the plaintiffs’ “radiation related injuries,” which they claim would prevent them from traveling to Japan at all.  The court also considered “The U.S. also has a strong interest in seeing that members of the Armed Forces are compensated for their service. Especially as it is the V.A. system and the U.S. taxpayers who will ultimately pay for the injuries to Plaintiffs.”

Fukushima Diary was directly informed of this by Paul C. Garner, ESQ., the attorney of the plaintiffs.

 

By having the court in U.S, the Sailors can go forward with Class Action. Up to 70,000 U.S. citizens were potentially affected by the radiation and will be able to join the class action suit. This “Class Action” is not granted in Japanese court. It can be the major reason why Tepco tried to transfer the case from U.S. to Japan so they can minimize the compensation value.

 

Additionally, the Court granted TEPCO’s motion to dismiss Plaintiffs’ design defect claim of the nuclear plant, however the court admitted the plaintiffs to add more defendants to consist of General Electric, EBASCO, Toshiba, Hitachi and the builders of Fukushima nuclear reactors.

 

In the decision, the court agreed with Plaintiffs that their Complaint is not barred by the firefighter’s rule. As alleged, the nuclear accident was independent of the earthquake that summoned the U.S. Navy. Although the Fukushima plant meltdown occurred in part due to the earthquake and tsunami, Plaintiffs allege the ultimate failure of Fukushima plant was a result of TEPCO’s inadequate preparation for a foreseeable natural disaster and negligence in designing and maintaining the Fukushima plant.

 

The amended pleading shall be filed by 11/18/2014.

Cooper-Order on Motion to Dismiss Sac102814

Cooper-second Tepco Press Release

 

_____

Français :

Les marins US gagnent une décision judiciaire clé pour avancer dans leur recours collectif contre Tepco, GE, Toshiba, Hitachi etc.

 

Article lié : La plainte des marins de l’US Navy fait référence au Fukushima Diary

Le juge fédéral Janis L. Sammartino a pris la décision de laisser avancer les marins de l’US Navy contre Tepco à la United States District Court de San Diego. Tepco insistait pour que la cour soit au Japon parce que “la plupart des témoins sont au Japon” et que “le gouvernement japonais pourrait refuser de donner des informations cruciales ou empêcher les témoins de se rendre dans une cour américaine”. Le juge fédéral a néanmoins conclu que ce serait dans une cour américaine pour les “blessures liées à la radioactivité” des plaignants qu’ils affirment pouvoir les empêcher de faire le voyage jusqu’au Japon. La cour a aussi considéré que “Les U.S. ont également fort intérêt à voir les membres des forces armées indemnisées pour avoir rempli leur mission. En particulier attendu que c’est l’administration des vétérants et les contribuables américains qui, au final, payeront les indemnisations aux plaignants”.

Le Fukushima Diary en a été directement informé par M. Paul C. Garner, ESQ., le représentant des plaignants.

Les marins peuvent aller plus loin dans leur action collective en ayant leur cour aus U.S.A. Jusqu’à 70 000 citoyens américains ont été potentiellement affectées par la radioactivité et seront en mesure de se joindre à l’action collective. Les “actions collectives” n’existent pas dans la juridiction japonaise. C’est sans doute la raison essentielle pour laquelle Tepco a tenté de déplacer le procès au Japon, pour réduire le montant des indemnisations.

En outre, la Cour a accédé à la requête de TEPCO de rejeter la demande des plaignants de défaut de conception dans la centrale, néanmoins la cour a autorisé les plaignants à ajouter d’autres inculpations de sociétés telles que General Electric, EBASCO, Toshiba, Hitachi et les constructeurs des réacteurs de la centrale nucléaire de Fukushima.

Dans sa décision, la cour a reconnu aux plaignants que leur plainte n’est pas interdite par la règle des pompiers. Comme présumé, l’accident nucléaire a été indépendant du séisme à l’origine de l’intervention de la marine américaine. Les plaignants prétendent que l’effondrement de la centrale nucléaire de Fukushima a fondamentalement été du à la préparation inadéquate de TEPCO à une catastrophe naturelle prévisible et à leur négligence dans la conception et l’exploitation de la centrale de Fukushima même si les fusions dans la centrale de Fukushima sont en partie dues au séisme et au tsunami.

La plaidoirie amendée sera déposée vers le 18 novembre 2014.

Cooper-Instruction sur la Motion de débout Sac102814

 

 

 

No Relationship Between Moderate Adolescent Cannabis Use, Exam Results or IQ, Large UK Study Shows

Date: October 20, 2014
Source: European College of Neuropsychopharmacology (ECNP)
Summary: A large UK study has found that occasional adolescent cannabis use does not lead to poorer educational and intellectual performance, but that heavy cannabis use is associated with slightly poorer exam results at age 16.

A large UK study has found that occasional adolescent cannabis use does not lead to poorer educational and intellectual performance, but that heavy cannabis use is associated with slightly poorer exam results at age 16. The results come from the Avon Longitudinal Study of Parents and Children (ALSPAC, also known as “Children of the 90’s”) a long-term study that follows the health of children born in the Bristol area (UK) in 1991 and 1992. The work is being presented at the annual congress of the European College of Neuropsychopharmacology (ECNP) in Berlin.

The researchers analysed data from 2,612 children who had their IQ tested at the age of 8, and again at the age of 15. These children’s examination results were then factored in via the National Pupil Database. At the age of 15, each person in the study completed a survey on cannabis use. The researchers then used regression analysis to look at how cannabis use affected both intellectual and educational performance. A number of children could not be included in the final analyses (for example because they had experienced a head injury), leaving a total sample size of 2,235.

The researchers found two main points

  • Cannabis use appeared to be associated with decreased intellectual performance. Cannabis use was, however, highly correlated with other risky behaviours such as alcohol, cigarette and other drug use. When the researchers took these other behaviours into account, they found there was no relationship between cannabis use and lower IQ at age 15.
  • Heavier cannabis users (at least 50 times by age 15) however, did show marginally impaired educational abilities. These children tended to have poorer exam results (3% lower) on compulsory school exams taken at age 16, even after adjusting for childhood educational performance, as well as alcohol, cigarette and other drug use.

According to lead researcher, Claire Mokrysz (University College London):

“Our findings suggest cannabis may not have a detrimental effect on cognition, once we account for other related factors- particularly cigarette and alcohol use. This may suggest that previous research findings showing poorer cognitive performance in cannabis users may have resulted from the lifestyle, behaviour and personal history typically associated with cannabis use, rather than cannabis use itself.

People often believe that using cannabis can be very damaging to intellectual ability in the long-term, but it is extremely difficult to separate the direct effects of cannabis from other potential explanations. Adolescent cannabis use often goes hand in hand with other drug use, such as alcohol and cigarette smoking, as well as other risky lifestyle choices.

It’s hard to know what causes what- do kids do badly at school because they are smoking weed, or do they smoke weed because they’re doing badly? This study suggests it is not as simple as saying cannabis is the problem.

This is a potentially important public health message- the belief that cannabis is particularly harmful may detract focus from and awareness of other potentially harmful behaviours. However the finding that heavier cannabis use is linked to marginally worse educational performance is important to note, warranting further investigation.”

Commenting ECNP Chair, Professor Guy Goodwin (Oxford) said “This is a potentially important study because it suggests that the current focus on the alleged harms of cannabis may be obscuring the fact that its use is often correlated with that of other even more freely available drugs and possibly lifestyle factors. These may be as or more important than cannabis itself.

The researchers noted that the study has some limitations. For example, cannabis use was self-reported, and the measure of IQ taken at age 15 was an abbreviated version of the standard Wechsler IQ test.

Full details can be found in the abstract (however please note that the abstract shows a preliminary analysis; this may differ from the version which is currently being prepared for publication and which is described above).


Story Source:

The above story is based on materials provided by European College of Neuropsychopharmacology (ECNP). Note: Materials may be edited for content and length.


Cite This Page:

European College of Neuropsychopharmacology (ECNP). “No relationship between moderate adolescent cannabis use, exam results or IQ, large study shows.” ScienceDaily. ScienceDaily, 20 October 2014. .
Follow

Get every new post delivered to your Inbox.

Join 67 other followers